Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
4 evidence topics · 5 sources
Doses studied in the phase 2b trial: 25 mg, 10 mg, and 1 mg
“we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose evaluated for retreatment in phase 3: 25 mg
Capsule strength in investigator studies: 5 mg capsules given as five capsules
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote